Condition: Melanoma Stage III · B-cell Non Hodgkin Lymphoma · Pediatric ALL · Sponsor: Miltenyi Biomedicine GmbH
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
This description comes directly from the study's public registry record.
Clinical Trial Manager · +4922048306820 · clinicaltrials.gov@miltenyi.com
Always discuss trial participation with your own doctor first.
| Charité Universitätsmedizin Berlin | Berlin, Germany | Recruiting |
| Universitätsklinikum Köln | Cologne, Germany | Active Not Recruiting |
| Uniklinikum Erlangen | Erlangen, Germany | Active Not Recruiting |
| Universitätsmedizin Göttingen | Göttingen, Germany | Active Not Recruiting |
| Universitätsklinikum Münster | Münster, Germany | Recruiting |
| Universitätsklinikum Tübingen | Tübingen, Germany | Active Not Recruiting |
| Universitäts-Kinderklinik Würzburg | Würzburg, Germany | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06508775